Estrella Immunopharma Inc.

Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company that develops T-cell therapies for blood cancers and solid tumors in the United States. Its lead product candidates include EB103, in Phase I/II clinical trials for diffuse large B-cell lymphoma; EB104, in pre-clinical trials for diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, in pre-clinical trials for systemic lupus erythematosus. The company offers ARTEMIS, a cell receptor platform for developing and commercializing T-cell therapies targeting CD19 and CD22 for hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited to develop solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Founded in 2006 and headquartered in EmeryVille, California, Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.

ESLA▼

Abbott Cooper PLLC Announces Investigation on Behalf of Estrella Immunopharma Stockholders

Abbott Cooper PLLC has announced an investigation into potential legal claims on behalf of stockholders of Estrella Immunopharma, Inc. The investigation seeks to determine whether Estrella's board of directors violated its fiduciary duties or committed other wrongdoing. Estrella's common stock is listed on Nasdaq under the symbol ESLA. Stockholders interested in learning more about the investigation or their legal rights are encouraged to contact Abbott Cooper PLLC at no cost or obligation.

ESLA ▼

GlobeNewswire·72dRead more →